Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs

被引:2
|
作者
Reddy, Nishith R. [1 ,2 ]
Maachi, Hasna [3 ,9 ,10 ,11 ,12 ,13 ]
Xiao, Yini [1 ,2 ,3 ]
Simic, Milos S. [1 ,2 ]
Yu, Wei [1 ,2 ]
Tonai, Yurie [1 ,2 ]
Cabanillas, Daniela A. [1 ,2 ]
Serrano-Wu, Ella [1 ,2 ]
Pauerstein, Philip T. [1 ,4 ]
Tamaki, Whitney [5 ]
Allen, Greg M. [1 ,6 ,7 ,8 ]
Parent, Audrey V. [3 ]
Hebrok, Matthias [3 ,9 ,10 ,11 ,12 ,13 ]
Lim, Wendell A. [1 ,2 ,7 ]
机构
[1] Univ Calif San Francisco, UCSF Cell Design Inst, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Diabet Ctr, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA
[5] Univ Calif San Francisco, UCSF CoLabs, San Francisco, CA USA
[6] Univ Calif San Francisco, Parker Inst Canc Immunotherapy, San Francisco, CA USA
[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94118 USA
[8] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[9] Univ Hosp Rechts Isar MRI, Ctr Organoid Syst, Garching, Germany
[10] Tech Univ Munich, Garching, Germany
[11] Helmholtz Munich, Inst Diabet Organoid Technol, Helmholtz Diabet Ctr, Neuherberg, Germany
[12] Tech Univ Munich, Munich Inst Biomed Engn MIBE, Garching, Germany
[13] German Ctr Diabet Res DZD, Neuherberg, Germany
关键词
IMMUNE CELLS; IMMUNOTHERAPY; RECOGNITION; CHALLENGES; CANCER;
D O I
10.1126/science.adl4793
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Immune homeostasis requires a balance of inflammatory and suppressive activities. To design cells potentially useful for local immune suppression, we engineered conventional CD4+ T cells with synthetic Notch (synNotch) receptors driving antigen-triggered production of anti-inflammatory payloads. Screening a diverse library of suppression programs, we observed the strongest suppression of cytotoxic T cell attack by the production of both anti-inflammatory factors (interleukin-10, transforming growth factor-beta 1, programmed death ligand 1) and sinks for proinflammatory cytokines (interleukin-2 receptor subunit CD25). Engineered cells with bespoke regulatory programs protected tissues from immune attack without systemic suppression. Synthetic suppressor T cells protected transplanted beta cell organoids from cytotoxic T cells. They also protected specific tissues from unwanted chimeric antigen receptor (CAR) T cell cross-reaction. Synthetic suppressor T cells are a customizable platform to potentially treat autoimmune diseases, organ rejection, and CAR T cell toxicities with spatial precision.
引用
收藏
页数:14
相关论文
共 44 条
  • [31] Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells
    Corria-Osorio, Jesus
    Carmona, Santiago J. J.
    Stefanidis, Evangelos
    Andreatta, Massimo
    Ortiz-Miranda, Yaquelin
    Muller, Tania
    Rota, Ioanna A. A.
    Crespo, Isaac
    Seijo, Bili
    Castro, Wilson
    Jimenez-Luna, Cristina
    Scarpellino, Leonardo
    Ronet, Catherine
    Spill, Aodrenn
    Lanitis, Evripidis
    Romero, Pedro
    Luther, Sanjiv A. A.
    Irving, Melita
    Coukos, George
    NATURE IMMUNOLOGY, 2023, 24 (5) : 869 - 883
  • [32] ORTHOGONAL GENE ENGINEERING ENABLES CD8+T CELLS TO CONTROL TUMORS THROUGH A NOVEL TOX-INDIFFERENT SYNTHETIC EFFECTOR STATE
    Coukos, G.
    Corria-Osorio, J.
    Carmona, S.
    Stefanidis, S.
    Andreatta, M.
    Muller, T.
    Ortiz-Miranda, Y.
    Irving, M.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A3 - A3
  • [33] A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo
    Pantel, Austin
    Cheong, Cheolho
    Dandamudi, Durga
    Shrestha, Elina
    Mehandru, Saurabh
    Brane, Luke
    Ruane, Darren
    Teixeira, Angela
    Bozzacco, Leonia
    Steinman, Ralph M.
    Longhi, M. Paula
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (01) : 101 - 109
  • [34] Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer
    van Schalkwyk, May C. I.
    Papa, Sophie E.
    Jeannon, Jean-Pierre
    Urbano, Teresa Guerrero
    Spicer, James F.
    Maher, John
    HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 2013, 24 (03) : 134 - 142
  • [35] Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT)
    Cherkasova, Elena
    Malinzak, Elizabeth
    Rao, Sheila
    Senchenko, Vera N.
    Kudryavtseva, Anna V.
    Kiselev, Lev L.
    Takahashi, Yoshiyuki
    Harashima, Nanae
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    Lerman, Michael I.
    Childs, Richard W.
    BLOOD, 2009, 114 (22) : 193 - 193
  • [36] Engineering of CD8+ T cells with an HIV-specific synthetic notch receptor to secrete broadly therapeutic antibodies for combining antiviral humoral and cellular immune responses
    Meng, Lina
    Zhao, Haichi
    Chang, Shangkun
    Li, Weiting
    Tian, Yinghui
    Wang, Ruihong
    Wang, Libian
    Gu, Tiejun
    Wu, Jiaxin
    Yu, Bin
    Wang, Chu
    Yu, Xianghui
    MBIO, 2025,
  • [37] INVITRO STUDIES ON H-2 LINKED UNRESPONSIVENESS TO SYNTHETIC POLYPEPTIDE ANTIGENS .2. INDUCTION OF SUPPRESSOR CELLS IN BOTH RESPONSIVE AND UNRESPONSIVE MICE TO (T,G)-A-L AND GAT10
    HOWIE, S
    IMMUNOLOGY, 1977, 32 (03) : 301 - 308
  • [38] A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
    Hunter, Theresa
    Soldevila, Ferran
    Zhang, Yan
    Ross, Brittany
    Matsuda, Daiki
    Bao, Yanjie
    Li, John
    Nguyen, Michelle
    Butcher, Matthew
    Pica, MIchael
    Fernandez, Claudia
    Vestal, James
    Mondal, Goutam
    Kuo, Yi
    Chen, Jeffrey
    Nguyen, Josephine
    Choi, Young Yoon
    Galvan, Diana
    Duy Nguyen
    Jhung, Donald
    Sievers, Stuart
    Tanis, Steven
    Bentley, Cory
    Rosenzweig, Michael
    Karmali, Priya
    Bot, Adrian
    Aghajanian, Haig
    Adams, Gregor
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 34 - 35
  • [39] UTILIZATION OF THE MHC CLASS-I (H-2K(B)) PURIFIED MOLECULE AND ITS SYNTHETIC PEPTIDES FOR INHIBITION OF K(B)-SPECIFIC SUPPRESSOR T-CELLS AND THEIR INDUCTION INVIVO BY THE MHC PEPTIDES
    BRONDZ, BD
    ANFALOVA, TV
    PAVLOVA, LS
    PANKRATOVA, EV
    KOJICH, AG
    MOSHNIKOV, SA
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1993, 37 (06) : 627 - 633
  • [40] Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system
    Chang, Peter S.
    Chen, Yi-Chun
    Hua, Wei-Kai
    Hsu, Jeff C.
    Tsai, Jui-Cheng
    Huang, Yi-Wun
    Kao, Yi-Hsin
    Wu, Pei-Hua
    Wang, Po-Nan
    Chang, Yi-Fang
    Chang, Ming-Chih
    Chang, Yu-Cheng
    Jian, Shiou-Ling
    Lai, Jiann-Shiun
    Lai, Ming-Tain
    Yang, Wei-Cheng
    Shen, Chia-Ning
    Wen, Kuo-Lan Karen
    Wu, Sareina Chiung-Yuan
    PLOS ONE, 2024, 19 (08):